Novel diarylamides as orally active diuretics targeting urea transporters

Discovery of novel diarylamides as orally active diuretics targeting urea transporters

Urea transporters (UT) play a vital role in the mechanism of urine concentration and are recognized as novel targets for the development of salt-sparing diuretics. Thus, UT inhibitors are promising for development as novel diuretics. In this study the authors discovered a novel UT inhibitor with a diarylamide scaffold by high-throughput screening. Optimization of the inhibitor led to the identification of a promising preclinical candidate, N-[4-(acetylamino)phenyl]-5-nitrofuran-2-carboxamide (1H), with excellent in vitro UT inhibitory activity at the submicromolar level. The half maximal inhibitory concentrations of 1H against UT-B in mouse, rat, and human erythrocyte were 1.60, 0.64, and 0.13 μmol/L, respectively.

Further investigation suggested that 8 μmol/L 1H more powerfully inhibited UT-A1 at a rate of 86.8% than UT-B at a rate of 73.9% in MDCK cell models. Most interestingly, the authors found for the first time that oral administration of 1H at a dose of 100 mg/kg showed superior diuretic effect in vivo without causing electrolyte imbalance in rats. Additionally, 1H did not exhibit apparent toxicity in vivo and in vitro, and possessed favorable pharmacokinetic characteristics. 1H shows promise as a novel diuretic to treat hyponatremia accompanied with volume expansion and may cause few side effects.

###

Article reference: Shun Zhang, Yan Zhao, Shuyuan Wang, Min Li, Yue Xu, Jianhua Ran, Xiaoqiang Geng, Jinzhao He, Jia Meng, Guangying Shao, Hong Zhou, Zemei Ge, Guangping Cheng, Runtao Li, Baoxue Yang, Discovery of novel diarylamides as orally active diuretics targeting urea transporters,

Acta Pharmaceutica Sinica B

, 2021, ISSN 2211-3835,

https:/

/

doi.

org/

10.

1016/

j.

apsb.

2020.

06.

001

Keywords: Urea transporter inhibitor, Diuretic, Structure optimization, Oral administration

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.

Acta Pharmaceutica Sinica B (APSB)

is a monthly journal, in English, which publishes significant original research articles, rapid communications and high-quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
For more information please visit

https:/

/

www.

journals.

elsevier.

com/

acta-pharmaceutica-sinica-b/

Editorial Board:

https:/

/

www.

journals.

elsevier.

com/

acta-pharmaceutica-sinica-b/

editorial-board

APSB is available on

ScienceDirect

.

Submissions to APSB may be made using

Editorial Manager®

.

CiteScore: 10.5

Impact Factor: 7.097

5-Year Impact Factor: 7.865

Source Normalized Impact per Paper (SNIP): 2.210

SCImago Journal Rank (SJR): 1.792

ISSN 2211-3835